New Delhi: Serum Institute of India, the country’s largest vaccine maker, on Wednesday announced the launch of its indigenously developed intra-nasal vaccine, Nasovac, for preventing H1N1 infections.
The single dose vaccine, fitted at the top of a syringe, is just to be sniffed once in each nostril, making it a painless prevention mode, the company said in a statement.
The vaccine is approved by the Drug Controller General of India (DCGI) for usage by any individual above three years of age, except pregnant women, and is economically priced so that it is affordable for the masses.
“Last year, we saw the panic due to fears about the H1N1 pandemic. I am happy that Serum has done its part in making the country self-reliant in creating vaccines for preventing pandemic influenza in the future,” Serum Institute of India chairman Cyrus Poonawalla said.
With the outbreak of H1N1 infections in 2009, the Serum Institute, in consultation with the World Health Organisation (WHO) and the Ministry of Health, had started work on the H1N1 vaccine.
The company is also working on an influenza vaccine under WHO guidance.
Serum Institute of India is the world’s largest DTP (Triple) and measles vaccine manufacturer. The company’s products are exported to over 130 countries worldwide.